4/21/2010- Morgan Stanley analysts are initiating coverage of Aveo Pharmaceuticals (NASDAQ:AVEO) with an overweight rating and $15 price target.
Analysts Steven Harr and Sara Slifka said, "We expect Tivozanib,...
AVEO
Detailed Quote (AVEO)
|
Detailed Quote (AVEO)
|